KALA BIO (KALA) Competitors $6.43 -0.04 (-0.62%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends KALA vs. AGLE, OVID, IMUX, MCRB, AVTX, IFRX, DERM, ANL, CDTX, and VXRTShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Aeglea BioTherapeutics (AGLE), Ovid Therapeutics (OVID), Immunic (IMUX), Seres Therapeutics (MCRB), Avalo Therapeutics (AVTX), InflaRx (IFRX), Journey Medical (DERM), Adlai Nortye (ANL), Cidara Therapeutics (CDTX), and Vaxart (VXRT). These companies are all part of the "medical" sector. KALA BIO vs. Aeglea BioTherapeutics Ovid Therapeutics Immunic Seres Therapeutics Avalo Therapeutics InflaRx Journey Medical Adlai Nortye Cidara Therapeutics Vaxart KALA BIO (NASDAQ:KALA) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Does the media refer more to KALA or AGLE? In the previous week, KALA BIO had 4 more articles in the media than Aeglea BioTherapeutics. MarketBeat recorded 4 mentions for KALA BIO and 0 mentions for Aeglea BioTherapeutics. KALA BIO's average media sentiment score of 0.20 beat Aeglea BioTherapeutics' score of 0.00 indicating that KALA BIO is being referred to more favorably in the media. Company Overall Sentiment KALA BIO Neutral Aeglea BioTherapeutics Neutral Which has higher earnings and valuation, KALA or AGLE? KALA BIO has higher revenue and earnings than Aeglea BioTherapeutics. KALA BIO is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BIO$3.89M7.62-$42.20M-$12.47-0.52Aeglea BioTherapeutics$2.33M0.00-$83.82M-$75.59N/A Is KALA or AGLE more profitable? KALA BIO has a net margin of 0.00% compared to Aeglea BioTherapeutics' net margin of -22,195.36%. Aeglea BioTherapeutics' return on equity of -132.05% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -448.61% -69.37% Aeglea BioTherapeutics -22,195.36%-132.05%-146.87% Which has more volatility and risk, KALA or AGLE? KALA BIO has a beta of -2.13, suggesting that its share price is 313% less volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500. Do insiders and institutionals have more ownership in KALA or AGLE? 24.6% of KALA BIO shares are held by institutional investors. 8.3% of KALA BIO shares are held by insiders. Comparatively, 6.6% of Aeglea BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate KALA or AGLE? KALA BIO currently has a consensus price target of $15.00, suggesting a potential upside of 133.28%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts clearly believe KALA BIO is more favorable than Aeglea BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Aeglea BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer KALA or AGLE? KALA BIO received 46 more outperform votes than Aeglea BioTherapeutics when rated by MarketBeat users. Likewise, 66.82% of users gave KALA BIO an outperform vote while only 54.16% of users gave Aeglea BioTherapeutics an outperform vote. CompanyUnderperformOutperformKALA BIOOutperform Votes30066.82% Underperform Votes14933.18% Aeglea BioTherapeuticsOutperform Votes25454.16% Underperform Votes21545.84% SummaryKALA BIO beats Aeglea BioTherapeutics on 14 of the 17 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.81M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.524.8587.8613.46Price / Sales7.62374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book4.3210.216.946.30Net Income-$42.20M$153.61M$119.12M$225.93M7 Day Performance-4.88%-2.00%-1.84%-1.32%1 Month Performance22.71%-7.47%-3.65%0.60%1 Year Performance7.71%31.80%31.64%26.23% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO4.0824 of 5 stars$6.43-0.6%$15.00+133.3%+7.8%$29.81M$3.89M-0.5230AGLEAeglea BioTherapeuticsN/AN/AN/AN/A$48.64M$2.33M-0.1669OVIDOvid Therapeutics4.4265 of 5 stars$1.04+1.0%$4.04+288.5%-68.5%$73.14M$390,000.00-2.2160Analyst RevisionNews CoverageIMUXImmunic3.0786 of 5 stars$1.07+1.9%$12.25+1,044.9%-3.6%$94.58MN/A0.0070MCRBSeres Therapeutics3.8903 of 5 stars$0.81+19.0%$5.08+524.6%-16.1%$117.54M$126.32M0.00233Analyst UpgradeHigh Trading VolumeAVTXAvalo Therapeutics2.3577 of 5 stars$10.90-1.4%N/A-47.4%$114.85M$1.92M0.0040Positive NewsIFRXInflaRx3.0863 of 5 stars$2.04+6.3%$8.00+292.2%+34.2%$113.06M$70,000.000.0060Gap UpDERMJourney Medical3.2183 of 5 stars$5.23-2.2%$9.38+79.3%N/A$110.89M$79.18M-5.5690Analyst RevisionPositive NewsANLAdlai Nortye2.948 of 5 stars$2.88-4.0%$9.00+212.5%-70.7%$110.70M$5M0.00127Gap UpCDTXCidara Therapeutics4.1784 of 5 stars$15.12-3.3%$30.50+101.7%+0.9%$110.14M$63.90M0.0090VXRTVaxart2.1372 of 5 stars$0.61-1.6%$3.00+393.6%-22.1%$110M$7.38M-1.48109Analyst RevisionNews Coverage Related Companies and Tools Related Companies Aeglea BioTherapeutics Competitors Ovid Therapeutics Competitors Immunic Competitors Seres Therapeutics Competitors Avalo Therapeutics Competitors InflaRx Competitors Journey Medical Competitors Adlai Nortye Competitors Cidara Therapeutics Competitors Vaxart Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KALA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALA Stock Alerts